No sleep score, no steps: this Signal smart ring from an ex-Google head is focused on cracking cuffless, calibration-less blood pressure readings
THE SO WHAT
A ring that ignores steps and sleep to chase calibration-free blood pressure is a bet that one clinically relevant metric beats a dashboard of vanity stats. Healthtech builders should read this as permission to narrow scope around a single hard problem instead of shipping yet another generalized wellness tracker.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechCan new drones, 3D printers defeat distance’s tyranny? RIMPAC aims to find out
The RIMPAC push to pair drones with 3D printers for ‘Uber for manufacturing’ is the military treating distributed, on-demand production as an operational requirement, not a demo. Industrial and logistics operators should read this as validation for local micro-factories, forward-deployed inventory, and autonomy-heavy resupply chains.
Deep & Emerging TechOracle is one notch above junk after S&P downgrade as AI data-centre spending burns through cash
Oracle’s S&P downgrade to BBB- on the back of a $250B data center build shows how quickly AI infra bets can stress even large balance sheets. Anyone scaling AI capex should pair build-out plans with hard payback models and contingency triggers before debt markets start repricing their story.
Deep & Emerging TechVitol Said to Be in Talks to Sell Shale Unit to Carnelian, EnCap
Vitol exploring a sale of VTX Energy Partners to Carnelian and EnCap suggests traders are trimming direct US upstream exposure while financial buyers still see value. Energy operators should read this as a portfolio-rotation moment—capital is not leaving hydrocarbons, but ownership and risk appetite are shifting.
Deep & Emerging TechChina beats Elon Musk’s Neuralink to the world’s first commercial brain-computer interface implant — car crash victim given coin-sized chip that turns neural signals into hand movements
Regulatory approval for commercial brain implants in China means BCI is moving from lab demo to regulated medical product in at least one major market. Anyone working on neuro-adjacent hardware or software now has to factor in a world where invasive interfaces may scale faster under non-US regimes.